Scott Ely

6.0k total citations
89 papers, 3.4k citations indexed

About

Scott Ely is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Scott Ely has authored 89 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 50 papers in Molecular Biology and 45 papers in Oncology. Recurrent topics in Scott Ely's work include Multiple Myeloma Research and Treatments (50 papers), Protein Degradation and Inhibitors (21 papers) and Lymphoma Diagnosis and Treatment (14 papers). Scott Ely is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Protein Degradation and Inhibitors (21 papers) and Lymphoma Diagnosis and Treatment (14 papers). Scott Ely collaborates with scholars based in United States, United Kingdom and Canada. Scott Ely's co-authors include Selina Chen‐Kiang, Rubén Niesvizky, Daniel M. Knowles, Ethel Cesarman, John P. Leonard, Morton Coleman, Ornella Flore, Amy Chadburn, John O’Leary and Peter Martin and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Scott Ely

87 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Ely United States 28 1.6k 1.3k 1.1k 872 737 89 3.4k
Catherine Spier United States 30 2.0k 1.2× 857 0.7× 1.8k 1.7× 559 0.6× 671 0.9× 73 3.6k
Alejandro Martı́n Spain 25 1.4k 0.8× 845 0.7× 861 0.8× 909 1.0× 533 0.7× 128 2.8k
Amanda F. Cashen United States 29 1.0k 0.6× 629 0.5× 1.4k 1.3× 891 1.0× 549 0.7× 121 2.9k
J Garcı́a-Conde Spain 35 2.0k 1.2× 954 0.7× 1.1k 1.0× 984 1.1× 792 1.1× 104 3.9k
Paula Marlton Australia 27 988 0.6× 1.1k 0.8× 1.0k 1.0× 1.2k 1.4× 789 1.1× 137 3.1k
TM Grogan United States 26 2.0k 1.2× 1.0k 0.8× 1.4k 1.3× 840 1.0× 711 1.0× 58 3.6k
Loïc Ysebaert France 33 1.5k 0.9× 804 0.6× 1.7k 1.6× 398 0.5× 1.1k 1.5× 139 3.7k
Nelly Robillard France 34 1.2k 0.7× 1.6k 1.2× 488 0.5× 1.7k 2.0× 641 0.9× 94 3.8k
Yoshitoyo Kagami Japan 35 1.9k 1.1× 739 0.6× 2.3k 2.1× 413 0.5× 705 1.0× 102 3.9k
José A. Martínez-Climent Spain 39 1.3k 0.8× 1.9k 1.5× 1.0k 1.0× 952 1.1× 865 1.2× 135 4.5k

Countries citing papers authored by Scott Ely

Since Specialization
Citations

This map shows the geographic impact of Scott Ely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Ely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Ely more than expected).

Fields of papers citing papers by Scott Ely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Ely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Ely. The network helps show where Scott Ely may publish in the future.

Co-authorship network of co-authors of Scott Ely

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Ely. A scholar is included among the top collaborators of Scott Ely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Ely. Scott Ely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ely, Scott, Peter A. Forsberg, Adriana Rossi, et al.. (2017). Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical Lymphoma Myeloma & Leukemia. 17(12). 825–833. 6 indexed citations
2.
Forsberg, Peter A., Adriana Rossi, Roger Pearse, et al.. (2016). Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). Blood. 128(22). 4518–4518. 4 indexed citations
3.
4.
Forsberg, Peter A., Adriana Rossi, Roger Pearse, et al.. (2015). A phase I study of the addition of high-dose lenalidomide to melphalan conditioning for autologous stem-cell transplant in relapsed or refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 15. e291–e292. 1 indexed citations
5.
Chiron, David, Maurizio Di Liberto, Peter Martin, et al.. (2014). Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. 4(9). 1022–1035. 204 indexed citations
6.
Niesvizky, Rubén, Tomer M. Mark, Maureen Ward, et al.. (2013). Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research. 19(6). 1534–1546. 20 indexed citations
7.
Geyer, Julia T., Rubén Niesvizky, David Jayabalan, et al.. (2013). IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Modern Pathology. 27(3). 375–381. 21 indexed citations
8.
Jungbluth, Achim A., Maurizio DiLiberto, Xiangao Huang, et al.. (2011). MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. Clinical Cancer Research. 17(13). 4309–4319. 79 indexed citations
9.
Martin, Peter, Amy Chadburn, Paul J. Christos, et al.. (2009). Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. Journal of Clinical Oncology. 27(8). 1209–1213. 234 indexed citations
10.
11.
Ely, Scott. (2009). Personalized medicine: individualized care of cancer patients. Translational research. 154(6). 303–308. 23 indexed citations
12.
Mark, Tomer M., David Jayabalan, Morton Coleman, et al.. (2008). Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British Journal of Haematology. 143(5). 654–660. 33 indexed citations
13.
Niesvizky, Rubén, Tara Naib, Paul J. Christos, et al.. (2007). Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy. British Journal of Haematology. 138(5). 640–643. 68 indexed citations
14.
Baughn, Linda B., Maurizio Di Liberto, Kaida Wu, et al.. (2006). A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. Cancer Research. 66(15). 7661–7667. 172 indexed citations
15.
Chiu, April, Langxing Pan, Zongdong Li, et al.. (2002). DNA Polymerase μ Gene Expression in B-Cell Non-Hodgkin's Lymphomas. American Journal Of Pathology. 161(4). 1349–1355. 4 indexed citations
16.
Tourigny, Michelle R., Josie Ursini‐Siegel, Hayyoung Lee, et al.. (2002). CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells. Immunity. 17(2). 179–189. 88 indexed citations
17.
Harvey, Ben‐Gary, Neil R. Hackett, Scott Ely, & Ronald G. Crystal. (2001). Host Responses and Persistence of Vector Genome Following Intrabronchial Administration of an E1−E3− Adenovirus Gene Transfer Vector to Normal Individuals. Molecular Therapy. 3(2). 206–215. 30 indexed citations
18.
Ely, Scott, A Werner, & Amy Chadburn. (2001). An angiocentric orbital lesion with an immature natural killer cell immunophenotype. Human Pathology. 32(3). 339–342. 3 indexed citations
19.
Ely, Scott, Amy Chadburn, C. Mitchell Dayton, Ethel Cesarman, & Daniel M. Knowles. (2000). Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 89(2). 445–452. 26 indexed citations
20.
Flore, Ornella, Shahin Rafii, Scott Ely, et al.. (1998). Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature. 394(6693). 588–592. 333 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Amanda F. Cashen Breakdown of academic impact, for papers by J Garcı́a-Conde Breakdown of academic impact, for papers by Paula Marlton Breakdown of academic impact, for papers by TM Grogan Breakdown of academic impact, for papers by Loïc Ysebaert Breakdown of academic impact, for papers by Nelly Robillard Breakdown of academic impact, for papers by Yoshitoyo Kagami Breakdown of academic impact, for papers by José A. Martínez-Climent
Rankless by CCL
2026